adenosine diphosphate has been researched along with Androgen-Independent Prostatic Cancer in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, JW; Unlu, S | 1 |
| Berlin, A; Bernardino, R; Brandão, LR; Chavarriaga, J; Fleshner, NE; Jiang, DM; Klaassen, Z; Roy, S; Sayyid, RK; Spratt, DE; Wallis, CJD | 1 |
| Foller, S; Grimm, MO; Leucht, K | 1 |
3 review(s) available for adenosine diphosphate and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
Emerging Role of PARP Inhibitors in Metastatic Prostate Cancer.
Topics: Adenosine Diphosphate; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Humans; Male; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Ribose | 2022 |
Poly(adenosine diphosphate-ribose) polymerase inhibitor combinations in first-line metastatic castrate-resistant prostate cancer setting: a systematic review and meta-analysis.
Topics: Adenosine Diphosphate; Anemia; BRCA1 Protein; BRCA2 Protein; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Ribose | 2023 |
[Combination therapy with poly(adenosine diphosphate-ribose) polymerase (PARPi) and androgen receptor signaling pathway (ARPi) inhibitors for metastatic castration-resistant prostate cancer].
Topics: Adenosine Diphosphate; Humans; Male; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Ribose; Signal Transduction | 2023 |